Nanjing King-Friend Biochemical Pharmaceutical Competitors and Similar CompaniesClear all

Nanjing King-Friend Biochemical Pharmaceutical's competitors and similar companies include Alembic Pharmaceuticals and UCB.

	Nanjing King-Friend Biochemical Pharmaceutical Nanjing King-Friend Biochemical Pharmaceutical (NKF, 南京健友生化制药股份有限公司) is a company that specializes in the research, production, and sales of medicines and health products.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
Founding Date	Founding Date 2000	Founding Date 2010	Founding Date 1928
Type	Type Public	Type Public	Type Public
Tags	Tags Healthcare bioengineering drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Nanjing, CN HQ Chengdu, CN Cork, IE Milano, IT Altrincham, GB Chicago, US	Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more
Employees	Employees 1,3606% decrease	Employees 14,858	Employees 9,052
Valuation ($)	Valuation ($) 3.3 b	Valuation ($) N/A	Valuation ($) 34.3 b
Financial
Revenue (est.)	Revenue (est.) ¥4b (FY, 2025)	Revenue (est.) ₹73.4b (FY, 2026)	Revenue (est.) €7.4b (FY, 2025)
Cost of goods	Cost of goods ¥2.4b (FY, 2025)	Cost of goods ₹19.8b (FY, 2026)	Cost of goods €1.4b (FY, 2025)
Gross profit	Gross profit ¥1.5b (FY, 2025)	Gross profit ₹54.1b (FY, 2026)	Gross profit €7.2b (FY, 2025)
Net income	Net income ¥581.5m (FY, 2025)	Net income ₹6.7b (FY, 2026)	Net income €1.6b (FY, 2025)